<DOC>
	<DOCNO>NCT02955940</DOCNO>
	<brief_summary>The purpose study provide continue supply ruxolitinib alone , ruxolitinib plus background cancer therapy , background cancer therapy alone subject Incyte-sponsored study ruxolitinib reach study objective terminate . This study also provide another mechanism report adverse event relate study drug safety .</brief_summary>
	<brief_title>An Open-Label Study Enable Continued Treatment Access Subjects Previously Enrolled Studies Ruxolitinib</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>Currently enrol receive treatment Incytesponsored clinical study ruxolitinib complete terminate . Currently tolerate treatment parent protocol . Currently benefit treatment ruxolitinib alone , ruxolitinib plus background cancer therapy , background cancer therapy alone , determine investigator . Have least stable disease , determine investigator . Has demonstrate compliance , assess investigator , parent study protocol requirement . Has permanently discontinue study treatment parent study reason . Able access ruxolitinib and/or background cancer therapy outside clinical study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Solid tumor</keyword>
	<keyword>ruxolitinib</keyword>
	<keyword>regorafenib</keyword>
	<keyword>capecitabine</keyword>
</DOC>